NTF3 and Charcot-Marie-Tooth disease type 4C: In this study, scAAV1.tMCK.NT-3 was delivered intramuscularly to 4-week-old Sh3tc2−/− mice, a model for CMT4C, and treatment efficacy was assessed at 6-month post-gene delivery.